Apellis Surges On FDA OK For Hemoglobin Therapy By Investing.com
By Dhirendra Tripathi Investing.com – Apellis Pharmaceuticals (NASDAQ:APLS) shares surged nearly 20% Monday after the U.S. Food and Drugs Administration gave its approval Friday for its therapy that increases hemoglobin in patients and reduces the need for blood transfusion. The company claims that the therapy, Empaveli, is the first and only targeted C3 therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria. C3 is a protein that contributes to immunity and triggers a response in the body when it is attacked by foreign elements or pathogens like virus and bacteria. Empaveli is approved for...
Continue reading